PRSS57 and COVID-19: Our analysis suggests that paclitaxel and bromocriptine, which dock with nucleocapsid and Nsp4 proteins can also effectively bind to c-Fos and thereby would be beneficial in inhibiting SARS-CoV2, as well as in alleviating lung injury observed in COVID-19 patients.